505 related articles for article (PubMed ID: 22693444)
1. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7.
Parrish NF; Wilen CB; Banks LB; Iyer SS; Pfaff JM; Salazar-Gonzalez JF; Salazar MG; Decker JM; Parrish EH; Berg A; Hopper J; Hora B; Kumar A; Mahlokozera T; Yuan S; Coleman C; Vermeulen M; Ding H; Ochsenbauer C; Tilton JC; Permar SR; Kappes JC; Betts MR; Busch MP; Gao F; Montefiori D; Haynes BF; Shaw GM; Hahn BH; Doms RW
PLoS Pathog; 2012; 8(5):e1002686. PubMed ID: 22693444
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV.
Cicala C; Arthos J; Fauci AS
J Transl Med; 2011 Jan; 9 Suppl 1(Suppl 1):S2. PubMed ID: 21284901
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded.
Quitadamo B; Peters PJ; Repik A; O'Connell O; Mou Z; Koch M; Somasundaran M; Brody R; Luzuriaga K; Wallace A; Wang S; Lu S; McCauley S; Luban J; Duenas-Decamp M; Gonzalez-Perez MP; Clapham PR
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118121
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic Correlates of HIV-1 Macrophage Tropism.
Arrildt KT; LaBranche CC; Joseph SB; Dukhovlinova EN; Graham WD; Ping LH; Schnell G; Sturdevant CB; Kincer LP; Mallewa M; Heyderman RS; Rie AV; Cohen MS; Spudich S; Price RW; Montefiori DC; Swanstrom R
J Virol; 2015 Nov; 89(22):11294-311. PubMed ID: 26339058
[TBL] [Abstract][Full Text] [Related]
5. Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
Peachman KK; Karasavvas N; Chenine AL; McLinden R; Rerks-Ngarm S; Jaranit K; Nitayaphan S; Pitisuttithum P; Tovanabutra S; Zolla-Pazner S; Michael NL; Kim JH; Alving CR; Rao M
PLoS One; 2015; 10(12):e0143895. PubMed ID: 26625359
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.
Wilen CB; Parrish NF; Pfaff JM; Decker JM; Henning EA; Haim H; Petersen JE; Wojcechowskyj JA; Sodroski J; Haynes BF; Montefiori DC; Tilton JC; Shaw GM; Hahn BH; Doms RW
J Virol; 2011 Sep; 85(17):8514-27. PubMed ID: 21715507
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.
Monini P; Cafaro A; Srivastava IK; Moretti S; Sharma VA; Andreini C; Chiozzini C; Ferrantelli F; Cossut MR; Tripiciano A; Nappi F; Longo O; Bellino S; Picconi O; Fanales-Belasio E; Borsetti A; Toschi E; Schiavoni I; Bacigalupo I; Kan E; Sernicola L; Maggiorella MT; Montin K; Porcu M; Leone P; Leone P; Collacchi B; Palladino C; Ridolfi B; Falchi M; Macchia I; Ulmer JB; Buttò S; Sgadari C; Magnani M; Federico MP; Titti F; Banci L; Dallocchio F; Rappuoli R; Ensoli F; Barnett SW; Garaci E; Ensoli B
PLoS One; 2012; 7(11):e48781. PubMed ID: 23152803
[TBL] [Abstract][Full Text] [Related]
8. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds.
Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J
J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646
[TBL] [Abstract][Full Text] [Related]
9. Distinct HIV-1 entry phenotypes are associated with transmission, subtype specificity, and resistance to broadly neutralizing antibodies.
Chikere K; Webb NE; Chou T; Borm K; Sterjovski J; Gorry PR; Lee B
Retrovirology; 2014 Jun; 11():48. PubMed ID: 24957778
[TBL] [Abstract][Full Text] [Related]
10. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
Ly A; Stamatatos L
J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
[TBL] [Abstract][Full Text] [Related]
11. Transmitted/founder and chronic HIV-1 envelope proteins are distinguished by differential utilization of CCR5.
Parker ZF; Iyer SS; Wilen CB; Parrish NF; Chikere KC; Lee FH; Didigu CA; Berro R; Klasse PJ; Lee B; Moore JP; Shaw GM; Hahn BH; Doms RW
J Virol; 2013 Mar; 87(5):2401-11. PubMed ID: 23269796
[TBL] [Abstract][Full Text] [Related]
12. The V2 loop of HIV gp120 delivers costimulatory signals to CD4
Goes LR; Sajani A; Sivro A; Olowojesiku R; Ray JC; Perrone I; Yolitz J; Girard A; Leyre L; Wibmer CK; Morris L; Gorini G; Franchini G; Mason RD; Roederer M; Mehandru S; Soares MA; Cicala C; Fauci AS; Arthos J
Proc Natl Acad Sci U S A; 2020 Dec; 117(51):32566-32573. PubMed ID: 33288704
[TBL] [Abstract][Full Text] [Related]
13. Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.
Martín J; LaBranche CC; González-Scarano F
J Virol; 2001 Apr; 75(8):3568-80. PubMed ID: 11264346
[TBL] [Abstract][Full Text] [Related]
14. Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.
Sterjovski J; Churchill MJ; Ellett A; Gray LR; Roche MJ; Dunfee RL; Purcell DF; Saksena N; Wang B; Sonza S; Wesselingh SL; Karlsson I; Fenyo EM; Gabuzda D; Cunningham AL; Gorry PR
Retrovirology; 2007 Dec; 4():89. PubMed ID: 18076768
[TBL] [Abstract][Full Text] [Related]
15. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
16. Unique Phenotypic Characteristics of Recently Transmitted HIV-1 Subtype C Envelope Glycoprotein gp120: Use of CXCR6 Coreceptor by Transmitted Founder Viruses.
Ashokkumar M; Aralaguppe SG; Tripathy SP; Hanna LE; Neogi U
J Virol; 2018 May; 92(9):. PubMed ID: 29491151
[TBL] [Abstract][Full Text] [Related]
17. Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer.
Zhao C; Princiotto AM; Nguyen HT; Zou S; Zhao ML; Zhang S; Herschhorn A; Farrell M; Pahil K; Melillo B; Sambasivarao SV; Abrams C; Smith AB; Madani N; Sodroski J
J Virol; 2019 Nov; 93(21):. PubMed ID: 31391272
[TBL] [Abstract][Full Text] [Related]
18. Envelope glycoprotein binding to the integrin α4β7 is not a general property of most HIV-1 strains.
Perez LG; Chen H; Liao HX; Montefiori DC
J Virol; 2014 Sep; 88(18):10767-77. PubMed ID: 25008916
[TBL] [Abstract][Full Text] [Related]
19. Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.
Lin G; Bertolotti-Ciarlet A; Haggarty B; Romano J; Nolan KM; Leslie GJ; Jordan AP; Huang CC; Kwong PD; Doms RW; Hoxie JA
J Virol; 2007 Sep; 81(18):9956-66. PubMed ID: 17609282
[TBL] [Abstract][Full Text] [Related]
20. CD4+ T cells support production of simian immunodeficiency virus Env antibodies that enforce CD4-dependent entry and shape tropism in vivo.
Francella N; Gwyn SE; Yi Y; Li B; Xiao P; Elliott ST; Ortiz AM; Hoxie JA; Paiardini M; Silvestri G; Derdeyn CA; Collman RG
J Virol; 2013 Sep; 87(17):9719-32. PubMed ID: 23824793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
